. 2022 Sep 5;113(11):3972–3979. doi: 10.1111/cas.15522

TABLE 2.

Gene‐based association analyses between cancer‐predisposing genes and lymphoma risk

	Number of pathogenic variant carrier (%)		OR (95% CI) ^a	p value ^a
	Lymphoma patients (N = 1,982)	Control (N = 37,592)	OR (95% CI) ^a	p value ^a
BRCA1	8 (0.40)	26 (0.07)	5.88 (2.65–13.02)	1.27 × 10⁻⁵
BRCA2	12 (0.61)	79 (0.21)	2.94 (1.60–5.42)	5.25 × 10⁻⁴
ATM	8 (0.40)	59 (0.16)	2.63 (1.25–5.51)	1.06 × 10⁻²
TP53	3 (0.15)	10 (0.03)	5.22 (1.43–19.02)	1.23 × 10⁻²
RAD51D	11 (0.56)	122 (0.33)	1.72 (0.92–3.19)	0.088
MSH2	1 (0.05)	3 (0.01)	7.00 (0.72–67.54)	0.093
NBN	1 (0.05)	50 (0.13)	0.39 (0.05–2.80)	0.346
EPCAM	1 (0.05)	8 (0.02)	2.66 (0.33–21.36)	0.359
PALB2	2 (0.10)	20 (0.05)	1.98 (0.46–8.47)	0.359
CHEK2	1 (0.05)	35 (0.09)	0.55 (0.08–4.04)	0.559
BARD1	1 (0.05)	19 (0.05)	1.03 (0.14–7.74)	0.974

Notes: Genes with no pathogenic variant carrier in lymphoma patients are not shown in this Table 2.

All results are shown in Table S4.

CI, confidence interval; OR, odds ratio.

^{^a}

Adjusted by age and sex in a logistic regression model.